Entera Bio (ENTX) vs Iambic Therapeutics (IAM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Iambic Therapeutics is the larger company by market cap ($621.4 million vs $575.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENTX | IAM |
|---|---|---|
| Share price | $3.31 | $13.11 |
| Market cap | $575.53M | $621.42M |
| 1-day change | +0.76% | -8.06% |
| YTD return | +70.36% | — |
| 1-year return | +30.63% | — |
| 5-year return | -3.64% | — |
| EPS (TTM) | $-0.40 | $-2.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $42.00K | — |
| Revenue growth (YoY) | -76.80% | — |
| Net income (latest FY) | $-11.44M | — |
| Gross margin | 0.00% | — |
| Operating margin | -27450.00% | — |
| Net margin | -27235.71% | — |
| 52-week high | $4.20 | $25.00 |
| 52-week low | $0.91 | $9.60 |
| Distance from 52-week high | -21.31% | -47.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +195.01% | +107.86% |
| Average volume | 438.35K | 714.92K |
| Shares outstanding | 174.14M | 47.40M |
| Employees | 27 | 171 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Entera Bio
ENTX stock →Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 27 employees
About Iambic Therapeutics
IAM stock →Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 171 employees
ENTX vs IAM FAQ
Which is bigger, Entera Bio or Iambic Therapeutics?
Iambic Therapeutics (IAM) is larger, with a market capitalization of $621.42M compared with $575.53M for Entera Bio (ENTX).
Are Entera Bio and Iambic Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.